Voyager Therapeutics, Inc. (VYGR) stock news
The latest Voyager Therapeutics, Inc. news and press releases. 0 news stories in the last 24 hours. VYGR stock report · Market news
Latest news
- Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer's Gene Therapy Dosing MarketBeat, Nov 16, 6:12 AM UTC
Voyager Therapeutics NASDAQ: VYGR expects a readout from its tau antibody study in the current quarter and plans to begin dosing patients in its Alzheimer's gene therapy program in the coming months, CEO Al Sandrock s... - Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Healthcare Conference 2026 Prepared Remarks Transcript Seeking Alpha, Nov 11, 10:29 PM UTC
Voyager Therapeutics, Inc. ( VYGR ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 2:00 PM EST Company Participants Alfred Sandrock - CEO & Director Conference Call Participants Paul Matteis Presentation Pau... - Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates Zacks Investment Research, Nov 5, 11:46 PM UTC
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.47 per share a year ago. - Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More Seeking Alpha, Oct 23, 9:19 PM UTC
Voyager Therapeutics, Inc. remains a Strong Buy, driven by dual anti-tau programs targeting Alzheimer's Disease with key catalysts in late 2026 and 2027. Company expects phase 1b PET imaging efficacy data for VY7523 i... - Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened Defense World, Oct 13, 7:21 AM UTC
Shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.08 and traded as low as $2.25. Voyage... - Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis Defense World, Sep 21, 6:29 AM UTC
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two busi... - Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Seeking Alpha, Sep 10, 8:57 AM UTC
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript - BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR Defense World, Sep 4, 7:31 AM UTC
BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 5,172,063 shares of the c...
Press releases
- Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 GlobeNewsWire, Oct 27, 12:01 PM UTC
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presen... - Voyager Announces CEO Succession Plan, Appoints Robin Swartz President GlobeNewsWire, Oct 21, 12:01 PM UTC
- Robin Swartz, Voyager's Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D. - Voyager to Present at Upcoming Investor Conferences GlobeNewsWire, Sep 1, 12:00 PM UTC
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company...
Headlines link to their publishers. Research data, not investment advice.